No Evidence for Memantine’s Benefit in Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-analysis (P10-9.018)

June 9, 2026Neurology

View at Publisher

Ask AI

Bookmark

Share

Key Points

The aim is to assess the efficacy and safety of memantine in the treatment of amyotrophic lateral sclerosis (ALS).
Conducted a systematic review and meta-analysis of existing studies on memantine in ALS.
Evaluated various outcomes related to efficacy and safety.
Included data from multiple clinical trials to draw comprehensive conclusions.
No significant benefits of memantine on ALS progression were found.
The findings suggest that memantine does not improve quality of life in ALS patients.
Safety profiles associated with memantine were consistent with previous studies, showing no unexpected adverse effects.

We only have this paper's title and publication details.

Systematic review and meta-analysis evaluate memantine's efficacy and safety in ALS, indicating no benefit.

To evaluate the efficacy and safety of memantine, an NMDA receptor antagonist, in ALS treatment.

No takes yet. Share an insight, caveat, or question.

Negida et al. (2026) studied this question.

View at Publisher

Ask AI

Bookmark

Share